Posted by Michael Wonder on 15 Jul 2025
Taxis Pharmaceuticals earns FDA QIDP designation for TXA14007, an investigational efflux pump inhibitor to combat antibiotic resistant pneumonia
15 July 2025 - Taxis Pharmaceuticals announced today that it has received an FDA qualified infectious disease product designation for TXA14007, its investigational efflux pump inhibitor in combination with levofloxacin for the treatment of hospital-acquired pneumonia and ventilator associated pneumonia.
Taxis' TXA14007 class of efflux pump inhibitors significantly enhanced the effectiveness of levofloxacin and other antibiotics against a wide range of drug resistant P. aeruginosa strains found in clinical settings.
